
Inventage Lab Inc. — Investor Relations & Filings
Inventage Lab Inc. is a biopharmaceutical company specializing in the development of advanced Drug Delivery Systems (DDS). The company's foundation is its proprietary microfluidics-based platform technology, Laminar-FluiDigm™, which is applied to pharmaceutical research and manufacturing. Inventage Lab operates two primary platforms: IVL-DrugFluidic® for developing and producing microsphere-based long-acting injectables, and IVL-GeneFluidic® for the formulation and manufacturing of Lipid Nanoparticles (LNPs) for nucleic acid and gene therapies. The company's pipeline is focused on treating chronic and refractory diseases, with key programs targeting androgenic alopecia (male pattern baldness) and Alzheimer's disease. Other development areas include drug re-discovery for conditions like rheumatic arthritis and multiple sclerosis, and collaborative projects for HIV treatments and mRNA-based therapies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-05-08 | Korean | |
| 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-05-08 | Korean | |
| 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-05-08 | Korean | |
| 투자판단관련주요경영사항(임상시험결과) (건강한 성인을 대상으로 IVL3003의 피하 또는 근육 주사와 ARICEPT®(도네페질) 정제 반복 투여 간 비교를 위한 공개, 탐색적, 연속적, 약동학, 단일용량상승 1상 임상시험) | 2026-04-20 | Korean | |
| 감자결정(종속회사의주요경영사항) | 2026-04-14 | Korean | |
| 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-04-13 | Korean |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44155434 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-05-08 | Korean | ||
| 44155201 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-05-08 | Korean | ||
| 44154928 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-05-08 | Korean | ||
| 34686113 | 투자판단관련주요경영사항(임상시험결과) (건강한 성인을 대상으로 IVL3003의 피하 또는 근육 주사와 ARICEPT®(도네페질) 정제 반복 투여 간 비교를 위한 공개, 탐색적, 연속적, 약동학, 단일용량상승 1상 임상시험) | 2026-04-20 | Korean | ||
| 34477097 | 감자결정(종속회사의주요경영사항) | 2026-04-14 | Korean | ||
| 34405765 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-04-13 | Korean | ||
| 34404463 | 주식등의대량보유상황보고서(일반) | 2026-04-13 | Korean | ||
| 33691404 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-04-07 | Korean | ||
| 33151905 | 주식등의대량보유상황보고서(일반) | 2026-04-02 | Korean | ||
| 33117562 | 정기주주총회결과 | 2026-03-31 | Korean | ||
| 33116562 | 주식매수선택권부여에관한신고 | 2026-03-31 | Korean | ||
| 33116498 | 사외이사의선임ㆍ해임또는중도퇴임에관한신고 | 2026-03-31 | Korean | ||
| 33013964 | 감사보고서제출 | 2026-03-23 | Korean | ||
| 33012286 | 사업보고서 (2025.12) | 2026-03-23 | Korean | ||
| 32981590 | 기업설명회(IR)개최 | 2026-03-19 | Korean | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Cardiol Therapeutics Inc.
Clinical-stage company developing anti-inflammatory therapi…
|
CRDL | CA | Professional, scientific and te… |
|
CASSAVA SCIENCES INC
Clinical-stage biotech developing treatments for Central Ne…
|
SAVA | US | Professional, scientific and te… |
|
Celcuity Inc.
Clinical-stage biotech developing targeted therapies for mu…
|
CELC | US | Professional, scientific and te… |
|
Cell Bio Human Tech Co., Ltd
Develops and manufactures cellulose-based nonwoven fabrics …
|
318160 | KR | Professional, scientific and te… |
|
CEL SCI CORP
Clinical-stage biotech developing immunotherapies for cance…
|
CVM | US | Professional, scientific and te… |
|
Celyad Oncology SA
Biotechnology company developing innovative CAR-T cell ther…
|
CYAD | BE | Professional, scientific and te… |
|
Ceres Power Holdings PLC
A developer of solid oxide technology for clean power and g…
|
CWR | GB | Professional, scientific and te… |
|
Certara, Inc.
Accelerates drug development using biosimulation software, …
|
CERT | US | Professional, scientific and te… |
|
CervoMed Inc.
A clinical-stage biotech developing treatments for age-rela…
|
CRVO | US | Professional, scientific and te… |
|
Chabiotech Co.,Ltd.
Develops cell/gene therapies and provides CDMO and bio-bank…
|
085660 | KR | Professional, scientific and te… |
Inventage Lab Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/17664/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=17664 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=17664 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=17664 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 17664}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Inventage Lab Inc. (id: 17664)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.